New combo aims to stop lymphoma relapse after powerful treatments
NCT ID NCT06242834
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether combining pembrolizumab (Keytruda) and tazemetostat can help prevent aggressive B-cell lymphoma from returning after patients have already received a stem cell transplant or CAR-T cell therapy. The study enrolls 32 adults and will measure how long they stay cancer-free. The goal is to see if this drug pair can overcome immune resistance that often allows the cancer to come back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab and tazemetostat
What this could lead to
If it works, this could offer a new way to prevent lymphoma from returning after stem cell or CAR-T therapy.
What could go wrong
This is a small, early-phase trial with only 32 participants, so results may not apply widely. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Iowa
Iowa City, Iowa, 52242, United States